FOLH1 and neoplasm: (ii) The in vivo key features of R-405 were its high efficacy against primary tumors (in the LLC1-PSMA model, 100% of mice exhibited a CR when treated with high doses of R-405), and the anti-tumor in situ vaccination effect which resulted in protection against distant challenge tumors.